Готові списки джерел за темами / Liver Cancer Diagnosis

Зміст

Статті в журналах
Дисертації
Книги
Частини книг
Тези доповідей конференцій
Звіти організацій

Добірка наукової літератури з теми "Liver Cancer Diagnosis"

Автор: Grafiati

Опубліковано: 4 червня 2021

Оновлено: 30 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Liver Cancer Diagnosis".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Liver Cancer Diagnosis"

TODA, GOTARO. "Diagnosis and treatment of liver cancer." Nihon Naika Gakkai Zasshi 87, no. 9 (1998): 1848–55. http://dx.doi.org/10.2169/naika.87.1848.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Punin, K. V. "Syphilis and liver cancer." Kazan medical journal 29, no. 1-2 (November 19, 2021): 48–56. http://dx.doi.org/10.17816/kazmj80418.

Повний текст джерела

Анотація:

The physician-therapist constantly has to meet with two diseases, the clinical picture of which is extremely similar to one another, but the prognosis of which, in most cases, is sharply different, if at the time the diagnosis is made and the appropriate treatment is undertaken. I mean here liver cancer and its tertiary luetic changes. Differential diagnosis of these two diseases is sometimes difficult even for a well-equipped clinical institution, represented by sufficiently large therapeutic forces, especially since it may not be within the power of a young district doctor.

Стилі APA, Harvard, Vancouver, ISO та ін.

Komemushi, Atsushi, Noboru Tanigawa, Chizu Koreeda, Shuji Kariya, Rie Yagi, Sachi Nakatani, Satoshi Suzuki, et al. "Recent diagnosis and therapy for liver cancer." Journal of Microwave Surgery 29 (2011): 39–43. http://dx.doi.org/10.3380/jmicrowavesurg.29.39.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Hami, H., A. Ayoujil, F. Z. Azzaoui, F. Habib, A. Soulaymani, A. Mokhtari, and A. Quyou. "Liver Cancer in Morocco: Diagnosis and Outcome." International Journal of Epidemiology 44, suppl_1 (September 23, 2015): i251. http://dx.doi.org/10.1093/ije/dyv096.462.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Yoshida, Hideo, Haruhiko Yoshida, Shuichiro Shiina, and Masao Omata. "Early liver cancer: concepts, diagnosis, and management." International Journal of Clinical Oncology 10, no. 6 (December 21, 2005): 384–90. http://dx.doi.org/10.1007/s10147-005-0537-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Sakamoto, Minoru. "2. Diagnosis and Surveillance of Liver Cancer." Japanese Journal of Radiological Technology 72, no. 1 (2016): 97–105. http://dx.doi.org/10.6009/jjrt.2016_jsrt_72.1.97.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Hatazawa, Jun. "Diagnosis: Liver metastasis of sigmoid colon cancer." Annals of Nuclear Medicine 15, no. 3 (June 2001): 216. http://dx.doi.org/10.1007/bf02987834.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Sada, Yvonne, Eric David, Hashem El-Serag, Hardeep Singh, and Jessica Davila. "Guideline adherence for diagnosis of liver cancer in veterans." Journal of Clinical Oncology 31, no. 31_suppl (November 1, 2013): 89. http://dx.doi.org/10.1200/jco.2013.31.31_suppl.89.

Повний текст джерела

Анотація:

89 Background: The incidence of hepatocellular cancer (HCC) is rising. Practice guidelines provide the recommended approach for HCC diagnosis, but adherence to diagnostic guidelines is unknown. Methods: In a national sample of veterans with confirmed HCC, we performed a retrospective chart review of patients with cirrhosis and a new liver mass on imaging between 2005 and 2011. Clinical data was used to assess adherence to American Association for the Study of Liver Diseases guidelines. Patients with inadequate data to assess guideline adherence (missing liver mass size, imaging technique, or diagnostic report) were excluded. We identified factors that contributed to guideline non-adherence. Initial liver mass date was the first date a liver mass was reported on imaging (CT, MRI, or ultrasound). Gold standard test date was the date a diagnosis of HCC could have been made by guideline recommended testing and criteria. Diagnosis date was the date a provider documented the diagnosis. Results: We reviewed charts for 380 patients. Overutilization of diagnostic tests after a gold standard test occurred in 112 patients (31%), and 17 (4%) had insufficient tests. Guidelines were not followed in 124 (33%). Of these 124, 68 (55%) had liver masses that increased in size during diagnostic work-up. The most common factors associated with guideline non-adherence were unnecessary testing such as biopsy after a gold standard image (43%) and the presence of a contraindication to a guideline recommended image or biopsy (12%). Patient factors (missed appointments, declining work-up) accounted for only 3% of cases. Median time between the initial liver mass and gold standard test was 15 days (IQR: 0-99). Median time between the initial liver mass and diagnosis was 50 days (IQR: 12-191). Most diagnoses were made by gastroenterology (51%), followed by primary care (19%), and oncology (10%). Conclusions: One-third of patients with HCC were not diagnosed based on guidelines. These concerns include confidence in diagnosis (lack of recognizing HCC diagnosis despite gold standard evidence) and over testing, which both lead to diagnostic delay. Our findings warrant further evaluation of contributory factors to develop interventions that improve the diagnostic process for HCC.

Стилі APA, Harvard, Vancouver, ISO та ін.

Liu, Da-Hua, Gui-Min Wen, Chang-Liang Song, Li-Jun Ji, and Pu Xia. "Amino acid profiles in the tissue and serum of patients with liver cancer." Open Medicine 17, no. 1 (January 1, 2022): 1797–802. http://dx.doi.org/10.1515/med-2022-0589.

Повний текст джерела

Анотація:

Abstract Most patients with liver cancer were found late and lost the chance of surgery. Liquid biopsy can monitor the risk of tumor recurrence and metastasis, quickly evaluate the curative effect of tumor treatment, and is conducive to early screening and auxiliary diagnosis of high-risk groups. Amino acid (AA) profiling has been used to the diagnosis and the prognosis for cancers. However, little was known about the profiles of AA of liver cancer. In this study, we used tRNA in Cancer database to analyze the AA levels in liver cancer tissues. Blood samples of patients with liver cancer were collected and analyzed using the automatic AA analyzer. We found that valine, isoleucine, and leucine were decreased significantly both in the plasma and the tumor tissues of patients with liver cancer. However, upregulation of methionine was observed in tissues and plasma of patients with liver cancer. Interestingly, tyrosine, and phenylalanine were decreased in tumor tissue but increased in the plasma of patients with liver cancer. This is the first report provided an overview of AA profile in both plasma and tissue for patients with liver cancer. AA levels can be used as diagnostic and prognostic markers of patients with liver cancer.

Стилі APA, Harvard, Vancouver, ISO та ін.

Guo, Hongyan, and Qingfeng Liu. "Clinical Value of Growth Differentiation Factor 15 Detection in the Diagnosis of Early Liver Cancer Based on Data Mining." BioMed Research International 2022 (November 17, 2022): 1–11. http://dx.doi.org/10.1155/2022/4448075.

Повний текст джерела

Анотація:

The incidence of liver cancer is increasing year by year, and how to effectively diagnose early-stage liver cancer and improve the survival rate of liver cancer patients has become one of the current research topics of concern. Aiming at this problem, it is of great significance for the diagnosis of early liver cancer. With the in-depth research on the diagnosis of early-stage liver cancer, the research on growth differentiation factor 15 is gradually carried out, and its performance advantages are of great significance to solve the problem of detection and diagnosis of early-stage liver cancer. This study can improve the accuracy of early diagnosis of liver cancer. The purpose of this paper is to study the application of data mining in the study of clinical value of growth and differentiation factor 15 detection and diagnosis of early liver cancer. In this paper, the data mining algorithm is analyzed, the performance of the algorithm is experimentally analyzed, and the relevant theoretical formulas are used to explain. The results showed that the expression level of GDF-15 was significant in early primary liver cancer (tumor diameter <2.5 cm). Different from normal liver tissue ( P < 0.01 ), there was a significant difference ( P < 0.01 ) compared with adjacent tissue ( P < 0.01 ). Serum GDF-15 can be used as a tumor marker for predicting early stage liver cancer. The high expression of GDF-15 in early stage liver cancer is an independent risk factor affecting the prognosis of liver cancer patients.

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Liver Cancer Diagnosis"

Tang, Yuen-fong, and 鄧婉芳. "Retrospective evaluation of the Barcelona Clinic Liver Cancer staging classification and treatment schedule and development of a newprognostic staging system with treatment guidelines for Hong Kongpatients with hepatocellular carcinoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B47324089.

Повний текст джерела

Анотація:

There are a number of existing staging systems for patients with hepatocellular carcinoma (HCC). Yet, Barcelona Clinic Liver Cancer (BCLC) staging classification is the only one which suggests treatment guidance. Although BCLC staging is widely used in Western countries, it may not fit in the management of HCC patients in Hong Kong as they mostly have different etiologies and have more aggressive treatment strategy when compared with their counterparts in Western countries. It is aimed in this thesis to develop a new prognostic staging system in conjunction with treatment guidelines for HCC patients in Hong Kong. Three thousand eight hundred and fifty six adult HCC patients presented to the Department of Surgery, Queen Mary Hospital between January 1995 and December 2008 were included. The patient data were randomly separated into a training set and a test set for scheme development and performance assessment respectively. Four established prognostic factors which have determinative roles in treatment, namely Eastern Cooperative Oncology Group performance status, Child-Pugh grade, tumor status, and presence of extrahepatic vascular invasion/metastasis, were selected in building the scheme. Cox proportional hazards regression on overall survival was used to derive a relative coefficient for each category of these four factors. Clinical knowledge in addition to the relative coefficients was involved in the proposal of the prognostic stages. Then a classification and regression tree analysis was performed to elicit a set of simple clinical decision rules given the factors. This tree-structured classifier was adjusted with clinical judgment and reconciled with the proposed prognostic staging system for treatment guidelines. This Hong Kong Combined Liver Cancer (HKCLC) prognostic classification scheme stratifies patients to stages I to V with distinct overall survival outcomes. Its performance was compared to BCLC scheme for their discriminatory ability as staging systems and effectiveness of treatment guidelines. The former used receiver operating characteristics (ROC) analysis and concordance index as measures of the ability to distinguish patients with different prognosis for overall survival. HKCLC staging had significantly larger 1-year, 3-year and 5-year area under ROC curve values and higher concordance index vis-a-vis BCLC staging. The latter compared the overall survival of patients who received different treatments. The overall survival of patients with the same BCLC stage and the same HKCLC stage but received HKCLC recommended treatments were compared with those received BCLC recommended treatments by Kaplan-Meier plots and log-rank test. HKCLC treatment guidelines had wider indications for more aggressive treatments than the BCLC treatment schedule, and demonstrated significant survival benefit in our patients.
published_or_final_version
Surgery
Master
Master of Philosophy

Стилі APA, Harvard, Vancouver, ISO та ін.

Sun, Stella, and 孫詠芬. "Biomarkers for early hepatocellular carcinoma: identification, characterization and validation." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B43572133.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Bettess, Michael David. "Purification, identification and characterisation of signals directing embryonic stem (ES) cell differentiation : a thesis submitted to the University of Adelaide for the degree of Doctor of Philosophy." Title page, contents and abstract only, 2001. http://web4.library.adelaide.edu.au/theses/09PH/09phb5644.pdf.

Повний текст джерела

Анотація:

Includes bibliographical references (leaves 142-168) Aim was the purification and identification of the early primitive ectoderm-like (EPL) cell induction signals within the medium conditioned by the human hepatocellular carcinoma cell line HepG2 and the localisation of the signals that induce EPL cell and primitive ectoderm formation.

Стилі APA, Harvard, Vancouver, ISO та ін.

Farah, Yasser Abdulhamid Elskay, and L. O. Averyanova. "Technologies for prevention liver cancer in Egypt." Thesis, ХНУРЕ, 2019. http://openarchive.nure.ua/handle/document/8373.

Повний текст джерела

Анотація:

Deaths from liver cancer are common, especially in East Asia and Pacific, South Asia, and parts of Sub-Saharan Africa, largely as a result of infection decades ago. Controlling the risk factors would not only reduce the incidence of liver cancer; it would also reduce the incidence of cirrhosis and its other complications. This paper will discuss the clinical implications of imaging in screening, diagnosis, staging, and follow-up of patients in liver malignancies.

Стилі APA, Harvard, Vancouver, ISO та ін.

Bayoumy, Hassan, and L. O. Averyanova. "Actual problems of stroke disease cure in Egypt." Thesis, Харків, ХНУРЕ, 2019. http://openarchive.nure.ua/handle/document/8375.

Повний текст джерела

Анотація:

The causes of stroke disease in Egypt are considered. The diagnosis of stroke is explained, and the used diagnostic instruments are studied. The prevention liver cancer is explained. The treatment of each of the causes of liver cancer is analyzed.

Стилі APA, Harvard, Vancouver, ISO та ін.

Fogelkvist, Elin, and Caroline Haraldsson. "Cancer : Yngre och medelålders kvinnors liv efter diagnosen ur ett omvårdnadsperspektiv." Thesis, Örebro universitet, Institutionen för hälsovetenskap och medicin, 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-22863.

Повний текст джерела

Анотація:

Bakgrund: I Sverige är cancer en av de främsta dödsorsakerna bland kvinnor. Genom att få ett livshotande besked, som att drabbas av cancer, kan individens livsvärld bli påverkad. Beskedet kan leda till att individen genomgår en kris. Syfte: Syftet med studien var att beskriva hur yngre och medelålders kvinnor lever sitt liv efter en cancerdiagnos. Metod: Studiens metod var beskrivande och genomfördes med kvalitativ innehållsanalys av självbiografier. Självbiografier lästes och meningsenheter togs ut. Meningsenheterna kodades och bildade kategorier som slutade i ett huvudtema. Resultat: Resultatet består av ett huvudtema: Leva i en förändrad livsvärld och sju kategorier, vilka är Trygghet – ovisshet, Glädje – sorg, Nära döden – nära livet, Acceptans – förnekelse, Hantering, Förändrade värderingar och nya insikter om livet, Förändrad framtid. Slutsatser: Kvinnornas livsvärld förändrades på så vis att vardagliga rutiner påverkades. Det uttrycktes en känsla av trygghet i sällskapet av sin familj och sina vänner. Kvinnorna kunde uppleva välbefinnande, trots sin sjukdom vid flertalet tillfällen. Sjukdomen ledde till förändrade värderingar och omprioritering av livet.

Стилі APA, Harvard, Vancouver, ISO та ін.

Howard, David Kingdon. "Leisure in the lives of older men coping and adaptation following prostate cancer diagnosis and treatment /." [Gainesville, Fla.] : University of Florida, 2004. http://purl.fcla.edu/fcla/etd/UFE0005603.

Повний текст джерела

Анотація:

Thesis (Ph.D.)--University of Florida, 2004.
Typescript. Title from title page of source document. Document formatted into pages; contains 234 pages. Includes Vita. Includes bibliographical references.

Стилі APA, Harvard, Vancouver, ISO та ін.

Quincey, Kerry. "Shifting masculinities amongst men diagnosed with breast cancer : a multi-method phenomenological inquiry." Thesis, De Montfort University, 2017. http://hdl.handle.net/2086/16683.

Повний текст джерела

Анотація:

Under-acknowledged both clinically and socially as a threat to men’s health, breast cancer in men continues to be a critical health issue, with complex ramifications for those affected. Research exploring men’s breast cancer experiences and their lives beyond the diagnosis remain limited. Hence, this inquiry asks ‘How do men describe breast cancer and their experiences of the illness?’ the aim, to advance understandings about men’s meaning-making of breast cancer and masculinity, and to ‘give voice’ to this under-researched population. Embedded theoretically and methodologically within a critical qualitative health framework, the research has two parts. Part one is a qualitative synthesis of nine existing international studies exploring men’s breast cancer experiences, following Noblit and Hare’s (1988) method for synthesising interpretive qualitative data. The outcomes of this synthesis were used to inform part two: a multi-method phenomenological exploration of men’s breast cancer accounts using verbal and visual data. Thirty-One British men recruited through NHS records, Breast Cancer Care, and social media platforms, used self-authored photographs to illustrate their breast cancer experiences, which they later discussed as part of extended semi-structured interviews. All data were analysed together using Interpretative Phenomenological Analysis (Smith & Osborn, 2003). Integrating and triangulating the findings from the two study phases, the on-going marginalisation of men across the breast cancer trajectory, and how this influences men’s experiences of, and adjustment to the illness, are revealed. Findings from the qualitative synthesis suggest current approaches to breast cancer care and advocacy serve to isolate men, potentially alienating and emasculating them; while patient management practices and informational resources unequivocally marginalise men. Findings from the new inquiry corroborate those from earlier studies, further illuminating the difficulties men encounter and some of their coping strategies. Specifically, three superordinate masculinities were identified: ‘threatened and exposed’, ‘protected and asserted’, and ‘reconsidered and reconfigured’. A schematic representation is presented to show how these interconnected masculinities are encountered, performed and utilised by men from pre-diagnosis through treatment and beyond as they manage, make sense of, and live through breast cancer. How and why men encounter/perform these different masculinities at different points in time across the breast cancer trajectory, and how this aids men’s adjustment to illness, and life beyond the diagnosis, is considered. The findings are expected to have both academic and real-world impact through informing future research, and recommendations for advocacy and intervention for improved future breast cancer care and practices.

Стилі APA, Harvard, Vancouver, ISO та ін.

Kypriotakis, Georgios. "A Year in Their Lives: Trajectories of Well-Being Among Patients Diagnosed with Advanced Stage Cancer." Case Western Reserve University School of Graduate Studies / OhioLINK, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=case1354853720.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Andersson, Westin Fidelie, and Elin Wistedt. "Barns upplevelser av att leva med cancer ett och ett halvt år efter diagnosen." Thesis, Högskolan i Borås, Institutionen för Vårdvetenskap, 2014. http://urn.kb.se/resolve?urn=urn:nbn:se:hb:diva-17589.

Повний текст джерела

Анотація:

I Sverige drabbas nästan ett barn om dagen av cancer. De vanligaste cancerformerna hos barn är leukemi och hjärntumör. De flesta barn insjuknar i en låg ålder. Sjukdomen innebär en lång behandling med svåra biverkningar och orsakar ett avbrott från det dagliga livet med förskola och lek. Detta kan få konsekvenser för deras fysiska och kognitiva utveckling. Den forskning som finns idag är bristfällig gällande barns upplevelser av att leva med cancer. Vårt syfte med studien är därför att beskriva barns upplevelser av sitt dagliga liv ett och ett halvt år efter en cancerdiagnos. Sex stycken avidentifierade intervjuer analyserades enligt Lundman och Hällgren Graneheims (2008) modell för kvalitativ innehållsanalys. I analysen fokuserade vi främst på barnens egna berättelser. Vår studie resulterade i fyra kategorier: Avskärmad från andra barn, Behov av stark känsla av kontroll, Annorlunda samspel i leken, Kroppen är annorlunda, samt nio underkategorier. I diskussionen lyfts vikten av lek, behovet av andra barn, känslan av kontroll samt sjuksköterskans roll för en god vårdrelation fram. Då behandlingstiden är lång med många efterkontroller träffar sjuksköterskan barnen under en längre period. Därför behöver sjuksköterskan som vårdar dessa barn en bättre inblick i hur barnen själva upplever sitt dagliga liv för att på bästa sätt kunna identifiera och tillgodose barnens unika behov. Ett barn som är välinformerat och delaktigt i sin egen vård upplever trygghet.
Program: Sjuksköterskeutbildning

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Книги з теми "Liver Cancer Diagnosis"

A, Curley Steven, ed. Liver cancer. New York: Springer, 1998.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Valverde, Benjamin J. Liver cancer: Causes, diagnosis, and treatment. Hauppauge, N.Y: Nova Science Publishers, 2011.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Reau, Nancy, and Fred Poordad. Primary liver cancer: Surveillance, diagnosis, and treatment. New York: Humana Press, 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Tito, Livraghi, Makuuchi Masatoshi, and Buscarini Luigi, eds. Diagnosis and treatment of hepatocellular carcinoma. London: Greenwich Medical Media, 1997.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Abou-Alfa, Ghassan K., Yuman Fong, Damian E. Dupuy, Jia-Hong Dong, and Gary Deng. Hepatobiliary cancer. Shelton, CT: People's Medical Publishing House-USA, 2014.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

L, Morris David, McArdle C. S, and Onik Gary 1952-, eds. Hepatic metastases: Diagnosis and management. Oxford: Butterworth-Heinemann, 1996.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

1941-, Kōjiro M., ed. Hepatocellular carcinoma: An atlas of its pathology. Tokyo: Springer-Verlag, 1987.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Hepatocellular carcinoma: Diagnosis and treatment. 2nd ed. Totowa, N.J: Humana, 2010.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Carr, Brian I. Hepatocellular carcinoma: Diagnosis and treatment. 2nd ed. Totowa, N.J: Humana, 2010.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

A life after diagnosis. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press, 2011.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Частини книг з теми "Liver Cancer Diagnosis"

Curley, Steven A. "Diagnosis and Treatment of Primary Gallbladder Cancer." In Liver Cancer, 117–35. New York, NY: Springer New York, 1998. http://dx.doi.org/10.1007/978-1-4612-1666-7_7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Thomas, Stephen, and Aytekin Oto. "Radiologic Diagnosis of Hepatocellular Carcinoma." In Primary Liver Cancer, 45–66. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-61779-863-4_3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Wesson, Russell N., and Andrew M. Cameron. "Differential Diagnosis of Focal Hepatic Lesions." In Primary Liver Cancer, 79–126. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-61779-863-4_5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Onishi, Hiromitsu, Takamichi Murakami, and Hironobu Nakamura. "Diagnosis of Hepatocellular Carcinoma: Multidetector-Row Computed Tomography and Magnetic Resonance Imaging." In Liver Cancer, 221–35. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-1-4020-9804-8_16.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Lopes, Roberto Heleno, Bruno Roberto Braga Azevedo, André Noronha Arvellos, Phillipe Abreu-Reis, and Alexandre Ferreira Oliveira. "Diagnosis of Colorectal Liver Metastases." In Colorectal Cancer Liver Metastases, 35–48. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-25486-5_4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Tomimatsu, Masahiko, and Hiroshi Obata. "Diagnosis of cholangiocellular carcinoma." In Primary Liver Cancer in Japan, 393–401. Tokyo: Springer Japan, 1992. http://dx.doi.org/10.1007/978-4-431-68177-9_39.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Sakaguchi, Seigo, Keiji Tohara, and Yoshihiko Oka. "Ultrasonographic diagnosis of hepatocellular carcinoma." In Primary Liver Cancer in Japan, 111–28. Tokyo: Springer Japan, 1992. http://dx.doi.org/10.1007/978-4-431-68177-9_12.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Inagaki, Yutaka, Masashi Unoura, and Kenichi Kobayashi. "Clinical features and diagnosis of primary liver cancer." In Primary Liver Cancer in Japan, 93–102. Tokyo: Springer Japan, 1992. http://dx.doi.org/10.1007/978-4-431-68177-9_10.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Matsui, Osamu, and Yuji Itai. "Diagnosis of primary liver cancer by computed tomography." In Primary Liver Cancer in Japan, 129–38. Tokyo: Springer Japan, 1992. http://dx.doi.org/10.1007/978-4-431-68177-9_13.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ohto, Masao, Fukuo Kondo, and Masaaki Ebara. "Pathology, diagnosis, and treatment for small liver cancer." In Primary Liver Cancer in Japan, 365–73. Tokyo: Springer Japan, 1992. http://dx.doi.org/10.1007/978-4-431-68177-9_36.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Liver Cancer Diagnosis"

Wang, Clinton J., Charlie A. Hamm, Brian S. Letzen, and James S. Duncan. "A probabilistic approach for interpretable deep learning in liver cancer diagnosis." In Computer-Aided Diagnosis, edited by Horst K. Hahn and Kensaku Mori. SPIE, 2019. http://dx.doi.org/10.1117/12.2512473.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Zhang, Baihua, Fu Wang, Xiang Chen, Hongze Lin, and He Huang. "Liver Cancer Diagnosis in CT Employing U-Net." In 2021 13th International Conference on Intelligent Human-Machine Systems and Cybernetics (IHMSC). IEEE, 2021. http://dx.doi.org/10.1109/ihmsc52134.2021.00034.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Reis, Gabriel Baêta Branquinho, Hugo Francisco da Fonseca Neto, Alice Jardim Zaccariotti, Daniel Bispo de Sousa, Silvaleide Ataides Assunção, Thiago Martins de Abreu, Fernando Santos de Azevedo, and Lanúscia Morais de Santana. "INVASIVE DUCTAL CARCINOMA IN A PATIENT WITH LI-FRAUMENI SYNDROME: A CASE REPORT." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2105.

Повний текст джерела

Анотація:

Introduction/Objectives: Breast cancer is one of the most common malignancies among women, with 10% resulting from genetic predisposition. Li-Fraumeni syndrome is an autosomal dominant disease that predisposes to multiple primary tumors and is responsible for less than 0.1% of breast cancers, being considered in early-onset tumors. The aim of this report was to describe a fast evolution of three primary tumors in a young patient with Li-Fraumeni syndrome, including ductal breast carcinoma. Case Report: In 2017, a 27-year-old female patient was diagnosed with malignant cancer of the right breast, Luminal HER KI67 70%, clinical stage IV (liver and lung), underwent first-line cancer treatment, maintaining endocrinotherapy and Double Block, with a positive genetic panel test for TP53 mutation, inferring SLF. In 2018, screening colonoscopy showed colon adenocarcinoma, pT53pN1, treated with total colectomy with ileal pouch, followed by suspension of endocrinotherapy and maintenance of Double Block and adjuvant FOLFOX. At the end of chemotherapy, endocrinotherapy was adopted again. Reassessment tests showed partial response in the liver, but the primary nodules were unchanged. Biopsy after thoracoscopy described lung adenocarcinoma, pT3pN2, submitted to adjuvant with Gemzar and Navelbine, followed by Double Block and interruption of endocrinotherapy. It evolved with the appearance of nodules in the right breast, suggestive of progression of breast disease, under treatment with Xeloda, Herceptin, and Perjeta, showing good clinical response. Discussion: Breast cancer in young people increases the possibility of heredity, thus raising the need for investigations of genetic syndromes. Although rare, the identification of FHL brings an important implication for the genetic counseling. Early diagnosis is the best form of management, enabling the preventive screening and intervention of multiple malignancies. Conclusion: Cases of breast cancer in young women should raise a suspected diagnosis of Li-Fraumeni syndrome, which can change the therapeutic and investigation of other cancers at an early stage.

Стилі APA, Harvard, Vancouver, ISO та ін.

Sammouda, Mohamed, Rachid Sammouda, Noboru Niki, and Kiyoshi Mukai. "Diagnosis of liver cancer based on the analysis of pathological liver color images." In Medical Imaging 2000, edited by Kenneth M. Hanson. SPIE, 2000. http://dx.doi.org/10.1117/12.387601.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Hao, Lijun, and Fei Xu. "An investigation on electronic nose diagnosis of liver cancer." In 2017 10th International Congress on Image and Signal Processing, BioMedical Engineering and Informatics (CISP-BMEI). IEEE, 2017. http://dx.doi.org/10.1109/cisp-bmei.2017.8302211.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Lee, Hansang, Helen Hong, Jinsil Seong, Jin Sung Kim, and Junmo Kim. "Survival prediction of liver cancer patients from CT images using deep learning and radiomic feature-based regression." In Computer-Aided Diagnosis, edited by Horst K. Hahn and Maciej A. Mazurowski. SPIE, 2020. http://dx.doi.org/10.1117/12.2551349.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

AlSalhi, Mohamad Saleh, Abdulaziz Mayuof Al Mehmadi, Aiman Abdoo, and Vadivel Masilamani. "Liver cancer diagnosis by fluorescence spectra of blood and urine." In Photonics and Optoelectronics Meetings 2011. SPIE, 2012. http://dx.doi.org/10.1117/12.923788.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Kim, Sangman, Seungpyo Jung, Youngju Park, Jihoon Lee, and Jusung Park. "Effective liver cancer diagnosis method based on machine learning algorithm." In 2014 7th International Conference on Biomedical Engineering and Informatics (BMEI). IEEE, 2014. http://dx.doi.org/10.1109/bmei.2014.7002866.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Priya, B. Lakshmi, S. Joshi Adaikalamarie, and K. Jayanthi. "Multi-temporal fusion of abdominal CT images for effective liver cancer diagnosis." In 2016 International Conference on Wireless Communications, Signal Processing and Networking (WiSPNET). IEEE, 2016. http://dx.doi.org/10.1109/wispnet.2016.7566377.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Kopriva, Ivica, Gorana Aralica, Marijana Popovic Hadzija, Mirko Hadzija, Laura-Isabelle Dion-Bertrand, and Xinjian Chen. "Hyperspectral imaging for intraoperative diagnosis of colon cancer metastasis in a liver." In Digital Pathology, edited by John E. Tomaszewski and Aaron D. Ward. SPIE, 2019. http://dx.doi.org/10.1117/12.2503907.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Liver Cancer Diagnosis"

Jin, Hongyu, and Man Zhang. LR-5 by LI-RADS under contrast enhanced ultrasonography manifests satisfactory diagnostic performance for hepatocellular carcinoma: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.10.0011.

Повний текст джерела

Анотація:

Review question / Objective: To evaluate the relative diagnostic sensitivity, specificity, and accuracy of LR-5 under contrast-enhanced ultrasonography (CEUS) LI-RADS system in the differential diagnosis of hepatocellular carcinoma (HCC). Information sources: A comprehensive and thorough search of literature was carried out through internationally acknowledged medical literature resources database, including PubMed/MEDLINE, EMBASE, Ovid, and Web of Science along with regional databases with key research words of (“hepatocellular carcinoma” OR “liver cancer” OR “liver tumor” OR “liver nodule” OR “liver mass” OR “liver lesion”) AND (“contrast-enhanced US” OR “contrast-enhanced ultrasonography” OR “contrast-enhanced ultrasound” OR “CEUS”) AND (“LI-RADS” OR “liver reporting and data system”) for studies published between January 2017 and June 2021. We limited the language used in the literature as English only.

Стилі APA, Harvard, Vancouver, ISO та ін.

Zhao, YiHao, and Dongbin Zhang. Efficacy and safety of trastuzumab combined with neoadjuvant chemotherapy in Chinese patients with HER-2 positive breast cancer: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.10.0003.

Повний текст джерела

Анотація:

Review question / Objective: To systematically evaluate the efficacy and safety of docetaxel combined with carboplatin and trastuzumab (TCH) neoadjuvant chemotherapy in Chinese patients with HER2-positive breast cancer. Condition being studied: Chinese patients who have been clinically diagnosed as HER-2 positive breast cancer, not complicated with basic diseases such as heart, liver and bone marrow, and who have received established surgery after chemotherapy and cooperated with follow-up. Eligibility criteria: Non-randomized controlled trials, animal experiments, literature review, non-docetaxel combined with carboplatin and trastuzumab as adjuvant therapy in Chinese breast cancer patients, and other drugs used in the intervention group or control group.

Стилі APA, Harvard, Vancouver, ISO та ін.

Hajarizadeh, Behzad, Jennifer MacLachlan, Benjamin Cowie, and Gregory J. Dore. Population-level interventions to improve the health outcomes of people living with hepatitis B: an Evidence Check brokered by the Sax Institute for the NSW Ministry of Health, 2022. The Sax Institute, August 2022. http://dx.doi.org/10.57022/pxwj3682.

Повний текст джерела

Анотація:

Background An estimated 292 million people are living with chronic hepatitis B virus (HBV) infection globally, including 223,000 people in Australia. HBV diagnosis and linkage of people living with HBV to clinical care is suboptimal in Australia, with 27% of people living with HBV undiagnosed and 77% not receiving regular HBV clinical care. This systematic review aimed to characterize population-level interventions implemented to enhance all components of HBV care cascade and analyse the effectiveness of interventions. Review questions Question 1: What population-level interventions, programs or policy approaches have been shown to be effective in reducing the incidence of hepatitis B; and that may not yet be fully rolled out or evaluated in Australia demonstrate early effectiveness, or promise, in reducing the incidence of hepatitis B? Question 2: What population-level interventions and/or programs are effective at reducing disease burden for people in the community with hepatitis B? Methods Four bibliographic databases and 21 grey literature sources were searched. Studies were eligible for inclusion if the study population included people with or at risk of chronic HBV, and the study conducted a population-level interventions to decrease HBV incidence or disease burden or to enhance any components of HBV care cascade (i.e., diagnosis, linkage to care, treatment initiation, adherence to clinical care), or HBV vaccination coverage. Studies published in the past 10 years (since January 2012), with or without comparison groups were eligible for inclusion. Studies conducting an HBV screening intervention were eligible if they reported proportion of people participating in screening, proportion of newly diagnosed HBV (participant was unaware of their HBV status), proportion of people received HBV vaccination following screening, or proportion of participants diagnosed with chronic HBV infection who were linked to HBV clinical care. Studies were excluded if study population was less than 20 participants, intervention included a pharmaceutical intervention or a hospital-based intervention, or study was implemented in limited clinical services. The records were initially screened by title and abstract. The full texts of potentially eligible records were reviewed, and eligible studies were selected for inclusion. For each study included in analysis, the study outcome and corresponding 95% confidence intervals (95%CIs) were calculated. For studies including a comparison group, odds ratio (OR) and corresponding 95%CIs were calculated. Random effect meta-analysis models were used to calculate the pooled study outcome estimates. Stratified analyses were conducted by study setting, study population, and intervention-specific characteristics. Key findings A total of 61 studies were included in the analysis. A large majority of studies (study n=48, 79%) included single-arm studies with no concurrent control, with seven (12%) randomised controlled trials, and six (10%) non-randomised controlled studies. A total of 109 interventions were evaluated in 61 included studies. On-site or outreach HBV screening and linkage to HBV clinical care coordination were the most frequent interventions, conducted in 27 and 26 studies, respectively. Question 1 We found no studies reporting HBV incidence as the study outcome. One study conducted in remote area demonstrated that an intervention including education of pregnant women and training village health volunteers enhanced coverage of HBV birth dose vaccination (93% post-intervention, vs. 81% pre-intervention), but no data of HBV incidence among infants were reported. Question 2 Study outcomes most relevant to the HBV burden for people in the community with HBV included, HBV diagnosis, linkage to HBV care, and HBV vaccination coverage. Among randomised controlled trials aimed at enhancing HBV screening, a meta-analysis was conducted including three studies which implemented an intervention including community face-to-face education focused on HBV and/or liver cancer among migrants from high HBV prevalence areas. This analysis demonstrated a significantly higher HBV testing uptake in intervention groups with the likelihood of HBV testing 3.6 times higher among those participating in education programs compared to the control groups (OR: 3.62, 95% CI 2.72, 4.88). In another analysis, including 25 studies evaluating an intervention to enhance HBV screening, a pooled estimate of 66% of participants received HBV testing following the study intervention (95%CI: 58-75%), with high heterogeneity across studies (range: 17-98%; I-square: 99.9%). A stratified analysis by HBV screening strategy demonstrated that in the studies providing participants with on-site HBV testing, the proportion receiving HBV testing (80%, 95%CI: 72-87%) was significantly higher compared to the studies referring participants to an external site for HBV testing (54%, 95%CI: 37-71%). In the studies implementing an intervention to enhance linkage of people diagnosed with HBV infection to clinical care, the interventions included different components and varied across studies. The most common component was post-test counselling followed by assistance with scheduling clinical appointments, conducted in 52% and 38% of the studies, respectively. In meta-analysis, a pooled estimate of 73% of people with HBV infection were linked to HBV clinical care (95%CI: 64-81%), with high heterogeneity across studies (range: 28-100%; I-square: 99.2%). A stratified analysis by study population demonstrated that in the studies among general population in high prevalence countries, 94% of people (95%CI: 88-100%) who received the study intervention were linked to care, significantly higher than 72% (95%CI: 61-83%) in studies among migrants from high prevalence area living in a country with low prevalence. In 19 studies, HBV vaccination uptake was assessed after an intervention, among which one study assessed birth dose vaccination among infants, one study assessed vaccination in elementary school children and 17 studies assessed vaccination in adults. Among studies assessing adult vaccination, a pooled estimate of 38% (95%CI: 21-56%) of people initiated vaccination, with high heterogeneity across studies (range: 0.5-93%; I square: 99.9%). A stratified analysis by HBV vaccination strategy demonstrated that in the studies providing on-site vaccination, the uptake was 78% (95%CI: 62-94%), significantly higher compared to 27% (95%CI: 13-42%) in studies referring participants to an external site for vaccination. Conclusion This systematic review identified a wide variety of interventions, mostly multi-component interventions, to enhance HBV screening, linkage to HBV clinical care, and HBV vaccination coverage. High heterogeneity was observed in effectiveness of interventions in all three domains of screening, linkage to care, and vaccination. Strategies identified to boost the effectiveness of interventions included providing on-site HBV testing and vaccination (versus referral for testing and vaccination) and including community education focussed on HBV or liver cancer in an HBV screening program. Further studies are needed to evaluate the effectiveness of more novel interventions (e.g., point of care testing) and interventions specifically including Indigenous populations, people who inject drugs, men who have sex with men, and people incarcerated.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!